Establishing a xenograft model of patient-derived tumors that reflects the clinical characteristics of gastric cancer is very important for gastric cancer research. This model is widely used in many areas of tumor research, including screening new anti-tumor drugs. Drug testing and tumor resistance research. The PDX model is more clinically predictable and can better simulate the growth of patient tumors, replace specific patients with drug screening, and perform personalized anti-tumor treatments, or the clinical implementation of "virtual image" trials, which can help you Provide guidance. Some patients are benefiting from it. Although the PDX model of gastrointestinal tumors (especially colon cancer) has made great progress, the research on the PDX model of gastric cancer is still in its infancy. Experiments have confirmed that the histopathological characteristics, gene expression and drug response of the gastric cancer PDX model tumor are very consistent with the primary tumor, and its application in gastric cancer research inevitably requires individualized treatment of gastric cancer to promote research.